Systemic treatment for hepatocellular carcinoma

Česká verze

Authors: MUDr. Tokarčík Ján ¹; doc. MUDr. Slížová Dáša, CSc. ²; doc. MUDr. Andrašina Igor, CSc. ³; Mgr. Vaculová Jana, Ph.D. ⁴
Authors place of work: IV. interná klinika LF UPJŠ a UN L. Pasteura, Košice, Slovenská republika ¹; Ústav anatomie, LF UK, Hradec Králové ²; Klinika rádioterapie a onkológie LF UPJŠ a VOÚ, Košice, Slovenská republika ³; Ústav patologie, LF OU a FNO, Ostrava ⁴
Published in the journal: Klin Onkol 2020; 33(5): 356-361
Category: Přehled
doi: https://doi.org/10.14735/amko2020356

Summary

Background: Hepatocellular carcinoma (HCC) is one of the most common types of cancer with increasing incidence. It accounts for approximately 90% of primary liver cancers and it is a significant global health problem. Globally, it represents the 5th most common disease and it is considered to be the third most common cause of cancer related deaths. The occurrence of HCC is related to environmental factors, eating habits and lifestyle. It is more common in men than in women. The highest incidence of HCC is in Southeast Asia, China, West and Central Africa, and among immigrants from high-risk areas in the United States. In North America, Europe and Japan, hepatitis C virus infection is its major risk factor along with alcohol consumption. Modern therapeutic methods improved the results of the treatment in patients with HCC. In early stages of HCC, curative treatment, surgical resection, liver transplantation, and radiofrequency ablation are possible. In advanced disease, local chemotherapy and systemic targeted therapy have prolonged survival.

Purpose: The aim of the article is to present the possibilities of systemic treatment of HCC in first and second lines of the treatment. Sorafenib was the first drug to be approved by the U. S. Food and Drug Administration for the treatment of advanced HCC and is a standard first-line drug. The first choice in the second line treatment of patients with progressive disease (after the treatment with sorafenib) is regorafenib. Nowadays, immunotherapy is also an adequate treatment option. Cabozantinib and ramucirumab represent additional treatment.

Keywords:

treatment – hepatocellular carcinoma – sorafenib – regorafenib – cabozantinib – ramucirumab

Zdroje

1. Llovet JM, Ducreux M. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56 (4): 908–943. doi: 10.1016/j.jhep.2011.12.001.

2. Otsuka T, Eguchi Y, Kawazoe S et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 2012; 42 (9): 879–886. doi: 10.1111/j.1872-034X.2012.00991.x.

3. Llovet J, Ricci S, Mazzaferro V et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25 (18 Suppl): LBA1.

4. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4): 378–390. doi: 10.1056/NEJMoa0708857.

5. Cheng AL, Guan Z, Chen Z et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 2012; 48 (10): 1452–1465. doi: 10.1016/j.ejca.2011.12.006.

6. Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10064): 56–66. doi: 10.1016/S0140-6736 (16) 32453-9.

7. Hollebecque A, Cattan S, Romano O et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011; 34 (10): 1193–1201. doi: 10.1111/j.1365-2036.2011.04860.x.

8. Kim JE, Ryoo B-Y, Ryu M-H et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011; 68 (5): 1285–1290. doi: 10.1007/s00280-011-1616-x.

9. Marrero JA, Kudo M, Venook AP et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016; 65 (6): 1140–1147. doi: 10.1016/j.jhep.2016.07.020.

10. Šálek T. Regorafenib v liečbe pacientov s hepatocelulárnym karcinómom predliečených sorafenibom. Farmakoterapia 2017; 124–128.

11. Matsui J, Funahashi Y, Uenaka T et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14 (17): 5459–5465. doi: 10.1158/1078-0432.CCR-07-5270.

12. Pörsök, Š, Pazderová, N, Zomborská et al. Systémová liečba pokročilého hepatocellárneho karcinómu. Onkológia 2019; 14 (6): 411–415.

13. Ikeda K, Kudo M, Kawazoe S et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017; 52 (4): 512–519. doi: 10.1007/s00535-016-1263-4.

14. Kudo M, Finn RS, Qin S et al. Lenvatinib vs. sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391 (10126): 1163–1173. doi: 10.1016/S0140-6736 (18) 30207-1.

15. NCCN Clinical Practice Guidelines in Oncology. Gastric cancer. Version 2.2013. [online]. Available from: https: //jnccn.org/view/journals/jnccn/11/5/article-p531.xml.

16. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23 (10): 2479–2516. doi: 10.1093/annonc/mds236.

17. Watanabe T, Itabashi M, Shimada Y et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012; 17 (1): 1–29. doi: 10.1007/s10147-011-0315-2.

18. Finn RS, Ryoo B-E, Merle P et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). [online]. Available from: https: //ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4004.

19. Finn RS, Merle P, Granito A et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. J Hepatol 2018; 69 (2): 353–358. doi: 10.1016/j.jhep.2018.04.010.

20. Nault JC. The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma. Lancet 2017; 389 (10064): 4–6. doi: 10.1016/S0140-6736 (16) 32480-1.

21. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. [online]. Available from: http: //dx.doi.org/10.1016/S0140-6736 (18) 30010-2.

22. NCCN Clinical Practice Guidelines in Oncology, Hepatobiliary Cancers, Version 1.2018. [online]. Available from: https: //pubmed.ncbi.nlm.nih.gov/19406039/.

23. Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology 2017; 92 (Suppl 1): 50–62. doi: 10.1159/000451016.

24. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology 2012; 1 (1): 48–55. doi: 10.4161/onci.1.1.18344.

25. El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389 (10088): 2492–2502. doi: 10.1016/S0140-6736 (17) 31046-2.

26. Sangro B, Melero I, Yau T et al. Nivolumab in sorafenib naive and experienced patients with advanced hepatocellular carcinoma (HCC): survival, hepatic safety, and biomarker assessments in CheckMate 040. [online]. Available from: https: //www.natap.org/2017/AASLD/AASLD_34.htm.

27. Crocenzi TS, El-Khoueiry AB, Yau TC et al. Nivolumab (nivo) in sorafenib (sor) -naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. [online]. Available from: https: //ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.4078.

28. Zhu AX, Finn RS, Edeline J et al. KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19 (7): 940–952. doi: 10.1016/S1470-2045 (18) 30351-6.

29. Llovet JM, Zucman-Rossi J, Pikarsky E et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016; 2: 16018. doi: 10.1038/nrdp.2016.18.

30. Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 379 (1): 54–63. doi: 10.1056/NEJMoa1717002.

31. Kelley RK, Verslype C, Cohn AL et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol 2017; 28 (3): 528–534. doi: 10.1093/annonc/mdw651.

32. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28 (5): 780–787. doi: 10.1200/JCO.2009.23.7537.

33. Zhu AX, Park JO, Ryoo BY et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015; 16 (7): 859–870. doi: 10.1016/S1470-2045 (15) 00050-9.

34. Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (2): 282–296. doi: 10.1016/S1470-2045 (18) 30937-9.

35. Zhu AX, Finn RS, Galle PR et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: patient reported outcome results across two phase III studies (REACH-2 and REACH). [online]. Available from: https: //www.annalsofoncology.org/article/S0923-7534 (19) 49084-4/fulltext.